RARE analyst estimates
Ultragenyx (RARE) analyst ratings, the average price target and its range, and every firm's latest call.
RARE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 14, 2026 | UBS | Ultragenyx initiated with a Neutral at UBS | $16.00 |
| Sep 21, 2026 | Barclays | Ultragenyx price target raised to $35 from $32 at Barclays | $35.00 |
| Sep 21, 2026 | Evercore ISI | Ultragenyx price target raised to $18 from $16 at Evercore ISI | $18.00 |
| Sep 18, 2026 | Canaccord Genuity | Ultragenyx Pharma (RARE) PT Raised to $39 at Canaccord | $39.00 |
| Sep 18, 2026 | Cantor Fitzgerald | Ultragenyx Pharma (RARE) PT Raised to $39 at Cantor Fitzgerald on FAYUVI Approval | $39.00 |
| Sep 18, 2026 | Morgan Stanley | Ultragenyx price target raised to $20 from $18 at Morgan Stanley | $20.00 |
| Sep 4, 2026 | Barclays | Ultragenyx price target lowered to $32 from $43 at Barclays | $32.00 |
| Sep 3, 2026 | Wells Fargo | Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight | $18.00 |
| Sep 3, 2026 | H.C. Wainwright | Ultragenyx price target lowered to $25 from $50 at H.C. Wainwright | $25.00 |
| Sep 3, 2026 | Canaccord Genuity | Ultragenyx price target lowered to $37 from $83 at Canaccord | $37.00 |
| Sep 3, 2026 | RBC Capital | Ultragenyx downgraded to Sector Perform from Outperform at RBC Capital | $19.00 |
| Sep 3, 2026 | Wedbush | Ultragenyx price target lowered to $23 from $30 at Wedbush | $23.00 |
| Sep 3, 2026 | Cantor Fitzgerald | Ultragenyx price target lowered to $33 from $103 at Cantor Fitzgerald | $33.00 |
| Sep 3, 2026 | Jefferies | Ultragenyx price target lowered to $28 from $77 at Jefferies | $28.00 |
| Sep 3, 2026 | Morgan Stanley | Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley | $18.00 |
- 21 firms rate RARE: 13 buy, 8 hold, 0 sell.
- The average price target is $25.45 from 11 analysts, from $16.00 to $39.00.
Updated 2026-11-02 23:11 UTC